Shots:

• The P-III DANUBE study involves assessing Imfinzi as monothx. & Imfinzi + Tremelimumab vs SOC CT as a 1L treatment for patients with unresectable- Stage IV (metastatic) UC whose tumor cells express high levels (≥25%) of PD-L1 & patients regardless of their PD-L1 expression respectively
• The P-III DANUBE study did not meet its 1EPs of OS while its safety & tolerability profile is consistent with previous studies
• Imfinzi (durvalumab) is a mAb targeting PD-L1- blocking the interaction of PD-L1 with PD-1 and CD80- being evaluated in multiple clinical studies for LA/m-BC and earlier stages of BC

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca